The FDA has issued a statement about the availability of immunoglobulin products, which many myositis patients depend upon for treatment of their disease. The statement says, in part: ” In the setting of the increased demand for Ig, other factors that ordinarily might not impact availability may have a greater effect. These could include uneven…
Continue Reading